⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Gilead’s Livdelzi ® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
businesswire.com
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
businesswire.com
GILD
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
businesswire.com
GILD
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
businesswire.com
GILD
Gilead Sciences Announces Third Quarter 2025 Financial Results
businesswire.com
GILD
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
businesswire.com
GILD
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
businesswire.com
GILD
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
businesswire.com
GILD
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
businesswire.com
GILD
Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
businesswire.com
GILD